Cancer Causes & Control

, Volume 19, Issue 2, pp 175–181

Quantifying the role of PSA screening in the US prostate cancer mortality decline

Authors

    • Fred Hutchinson Cancer Research Center
  • Alex Tsodikov
    • Department of BiostatisticsUniversity of California at Davis
    • Department of BiostatisticsUniversity of Michigan
  • Angela Mariotto
    • Division of Cancer Control and Population SciencesNational Cancer Institute
  • Aniko Szabo
    • Huntsman Cancer Institute
    • Medical College of Wisconsin
  • Seth Falcon
    • Fred Hutchinson Cancer Research Center
  • Jake Wegelin
    • Department of BiostatisticsUniversity of California at Davis
    • Virginia Commonwealth University
  • Dante diTommaso
    • Fred Hutchinson Cancer Research Center
    • Novartis Pharmaceuticals
  • Kent Karnofski
    • Fred Hutchinson Cancer Research Center
  • Roman Gulati
    • Fred Hutchinson Cancer Research Center
  • David F. Penson
    • Keck School of Medicine and Norris Cancer CenterUniversity of Southern California
  • Eric Feuer
    • Division of Cancer Control and Population SciencesNational Cancer Institute
Original Paper

DOI: 10.1007/s10552-007-9083-8

Cite this article as:
Etzioni, R., Tsodikov, A., Mariotto, A. et al. Cancer Causes Control (2008) 19: 175. doi:10.1007/s10552-007-9083-8

Abstract

Objective

To quantify the plausible contribution of prostate-specific antigen (PSA) screening to the nearly 30% decline in the US prostate cancer mortality rate observed during the 1990s.

Methods

Two mathematical modeling teams of the US National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network independently projected disease mortality in the absence and presence of PSA screening. Both teams relied on Surveillance, Epidemiology, and End Results (SEER) registry data for disease incidence, used common estimates of PSA screening rates, and assumed that screening, by shifting disease from distant to local-regional clinical stage, confers a corresponding improvement in disease-specific survival.

Results

The teams projected similar mortality increases in the absence of screening and decreases in the presence of screening after 1985. By 2000, the models projected that 45% (Fred Hutchinson Cancer Research Center) to 70% (University of Michigan) of the observed decline in prostate cancer mortality could be plausibly attributed to the stage shift induced by screening.

Conclusions

PSA screening may account for much, but not all, of the observed drop in prostate cancer mortality. Other factors, such as changing treatment practices, may also have played a role in improving prostate cancer outcomes.

Keywords

Prostate-specific antigen Prostate cancer Public health Computer simulation

Copyright information

© Springer Science+Business Media B.V. 2007